Abdominal Pain News and Research

RSS

Abdominal pain is traditionally described by its chronicity (acute or chronic), its progression over time, its nature (sharp, dull, colicky), its distribution (by various methods, such as abdominal quadrant (left upper quadrant, left lower quadrant, right upper quadrant, right lower quadrant) or other methods that divide the abdomen into nine sections), and by characterization of the factors that make it worse, or alleviate it.

Bayer's oral contraceptives may increase risk of blood clots, stroke or heart attack

Bayer HealthCare Pharmaceuticals, Inc. is aware of two studies published today in The British Medical Journal, ONLINE FIRST.

25 Apr 2011

Salix Pharmaceuticals receives three U.S. patents relating to rifaximin

Salix Pharmaceuticals, Ltd. today announced that the U.S. Patent and Trademark Office has issued three patents relating to rifaximin.

21 Apr 2011

KCMC uses Toshiba's diagnostic imaging systems to treat pediatric patients

As one of the leading pediatric centers in the United States, Kosair Children's Medical Center (KCMC) treats pediatric patients with conditions ranging from congenital heart disease to abdominal pain, to emergency trauma to juvenile diabetes and pediatric cancer.

20 Apr 2011

IBD patients at greater risk of death if infected with Clostridium difficile

Patients admitted to hospital with inflammatory bowel disease (IBD) face a sixfold greater risk of death if they become infected with Clostridium difficile, a new study has found. The researchers say IBD patients should be screened on admission to protect them from serious illness.

20 Apr 2011

How peppermint helps to relieve Irritable Bowel Syndrome

University of Adelaide researchers have shown for the first time how peppermint helps to relieve Irritable Bowel Syndrome, which affects up to 20% of the population.

20 Apr 2011

State Roundup: Mass. considers new health payment system

The California Public Employees' Retirement System is negotiating a lucrative pharmacy benefits management contract with Caremark Rx Inc., a company being sued for defrauding the pension fund of tens of millions of dollars (Lifsher, 4/16).

18 Apr 2011

Experts to discuss latest findings in IBD research at Rome meeting

Experts from 11 countries will gather this week in Rome to discuss innovative strategies for studying and treating Inflammatory Bowel Diseases.

12 Apr 2011

Pfizer to support immatics' IMA901 Phase III trial in advanced renal cell carcinoma

immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, today announced that Pfizer has agreed to support its pivotal Phase III trial with IMA901, its therapeutic cancer vaccine for advanced renal cell carcinoma.

11 Apr 2011

AJG publishes new review on Inflammatory Bowel Disease management

The American College of Gastroenterology published a new evidence-based systematic review on the management of Inflammatory Bowel Disease as a supplement to The American Journal of Gastroenterology for April 2011, a special issue entirely dedicated to IBD.

8 Apr 2011

AstraZeneca's vandetanib receives FDA approval in medullary thyroid cancer

AstraZeneca today announced that the U.S. Food and Drug Administration approved the orphan drug vandetanib for the treatment of medullary thyroid cancer that cannot be removed by surgery or that has spread to other parts of the body.

7 Apr 2011

AstraZeneca receives FDA approval for vandetanib to treat medullary thyroid cancer

The U.S. Food and Drug Administration today approved vandetanib to treat adult patients with late-stage (metastatic) medullary thyroid cancer who are ineligible for surgery and who have disease that is growing or causing symptoms.

7 Apr 2011

Results of study evaluating potential inhibitory effects of PPIs on Plavix presented at ACC 2011

Takeda Pharmaceuticals North America, Inc. announced the presentation of new study results, which evaluated the potential inhibitory effects of certain proton pump inhibitors (PPIs) on Plavix (clopidogrel bisulfate). The results showed that in healthy subjects, clopidogrel's active metabolite and inhibition of platelet function were reduced less by the co-administration of clopidogrel with dexlansoprazole or lansoprazole, rather than esomeprazole.

6 Apr 2011

South Sudan health workers face worst Kala-azar outbreak

South Sudan is facing the worst outbreak of Kala-azar in the past 10 years as health workers from Servant's Heart Relief race against the clock to stop the spread of the deadly disease.

5 Apr 2011

Study finds substantial increase in pediatric CT in hospital emergency departments

Computed tomography examinations of children in hospital emergency departments increased substantially from 1995 to 2008, according to a new study published online and in the June print edition of Radiology. Researchers said the findings underscore the need for collaboration among medical professionals to ensure that pediatric CT is appropriately ordered, performed and interpreted.

5 Apr 2011

Boehringer Ingelheim receives FDA approval for Viramune XR to treat HIV-1 infection

Boehringer Ingelheim Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has approved Viramune XR extended-release tablets, a one-pill, once-daily formulation of nevirapine for use in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults.

5 Apr 2011

LifeSpan medicine launches new health and wellness program for kids

LifeSpan medicine is excited to announce the launch of the LifeSpan Healthy Kids Program. There is nothing more important to a lifespan of health than a good start. Who would not want to have a better, healthier childhood for their kids than they themselves had?

1 Apr 2011

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

Merck, known as MSD outside of the United States and Canada, announced results from several new data analyses from the pivotal Phase III studies evaluating the addition of its investigational oral protease inhibitor VICTRELIS to peginterferon alfa-2b and ribavirin in adult patients with chronic hepatitis C virus genotype 1 infection.

1 Apr 2011

Vertex announces final results from Phase 3 REALIZE study against HCV

Vertex Pharmaceuticals Incorporated today announced final results from its pivotal Phase 3 REALIZE study that evaluated people with genotype 1 chronic hepatitis C whose prior treatment with pegylated-interferon and ribavirin was unsuccessful either because they relapsed, had a partial response or had a null response.

1 Apr 2011

Vertex announces interim results from VX-222 ongoing Phase 2 study against hepatitis C

Vertex Pharmaceuticals Incorporated today announced interim results from an ongoing Phase 2 study designed to assess the safety and tolerability of 12-week response-guided treatment regimens with its polymerase inhibitor, VX-222, and its protease inhibitor, telaprevir, in combination with pegylated-interferon and ribavirin in people with genotype 1 chronic hepatitis C who were new to treatment.

31 Mar 2011

Amgen announces top-line results from motesanib Phase 3 trial against NSCLC

Amgen, Millennium: The Takeda Oncology Company, and Takeda Pharmaceutical Company Limited today announced top-line results from the MONET1 pivotal Phase 3 trial evaluating motesanib administered in combination with paclitaxel and carboplatin in 1,090 patients with advanced non-squamous non-small cell lung cancer.

30 Mar 2011

Abdominal Pain News and Research

Further Reading

Bayer's oral contraceptives may increase risk of blood clots, stroke or heart attack

Salix Pharmaceuticals receives three U.S. patents relating to rifaximin

KCMC uses Toshiba's diagnostic imaging systems to treat pediatric patients

IBD patients at greater risk of death if infected with Clostridium difficile

How peppermint helps to relieve Irritable Bowel Syndrome

State Roundup: Mass. considers new health payment system

Experts to discuss latest findings in IBD research at Rome meeting

Pfizer to support immatics' IMA901 Phase III trial in advanced renal cell carcinoma

AJG publishes new review on Inflammatory Bowel Disease management

AstraZeneca's vandetanib receives FDA approval in medullary thyroid cancer

AstraZeneca receives FDA approval for vandetanib to treat medullary thyroid cancer

Results of study evaluating potential inhibitory effects of PPIs on Plavix presented at ACC 2011

South Sudan health workers face worst Kala-azar outbreak

Study finds substantial increase in pediatric CT in hospital emergency departments

Boehringer Ingelheim receives FDA approval for Viramune XR to treat HIV-1 infection

LifeSpan medicine launches new health and wellness program for kids

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

Vertex announces final results from Phase 3 REALIZE study against HCV

Vertex announces interim results from VX-222 ongoing Phase 2 study against hepatitis C

Amgen announces top-line results from motesanib Phase 3 trial against NSCLC

Industry Focus eBook - Cell biology (5th edition) eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News